- Funds will advance analysis into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with the goal of growing multivalent most cancers vaccines concentrating on a number of mutations
BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) — Elicio Therapeutics, a clinical-stage biotechnology firm growing a pipeline of novel immunotherapies for the remedy of most cancers and different illnesses, at present introduced that it has been awarded a $2.8 million grant from the Gastro-Intestinal Research Foundation (GIRF) in Chicago to fund analysis for 2 therapeutic most cancers vaccines. Both vaccines have been designed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) platform that “educates” T cells on the way to goal specific antigens, akin to mutated proteins in most cancers. ELI-007 is being developed to focus on the BRAF gene mutation, and ELI-008 is being developed to focus on hotspot mutations in p53 in stable tumors together with colorectal most cancers, melanoma and non-small cell lung most cancers (NSCLC). BRAF V600E mutations are current in 40% of melanoma, 10% of colon most cancers and a pair of% of lung most cancers whereas mutations in p53 are present in roughly 60% of sufferers with stable tumors.
“We are excited to receive the grant from GIRF and look forward to broadening our pipeline by developing ELI-007 and ELI-008 to target these key cancer mutations. p53 hotspot mutants and mutant BRAF are examples of public cancer neoantigens shared across many patients and tumor types with limited therapeutic options for providing durable therapeutic benefit,” mentioned Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio. “By targeting vaccine components to the lymph nodes, the AMP strategy is ideally suited to enhance tumor-specific immunity with the potential to eradicate tumors and promote durable patient responses.”
Previous analysis has proven that T cells can reply to the driver mutation V600E in BRAF and that switch of tumor-infiltrating lymphocytes that acknowledge mutated BRAF resulted in a sturdy full response in a case research. In addition, small molecule inhibitors generate preliminary responses in BRAF V600E-mutated melanoma, however these aren’t sustained due to resistance resulting from different development signaling pathways, and few preliminary responses happen in BRAF-mutated colon most cancers. The protein expression of BRAF V600E is maintained at excessive ranges in these tumors suggesting that they might be inclined to T cells particular for the mutated BRAF.
Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer, added, “These mutations are recognized by some patients’ T cells at low levels, and when T cells recognizing tumor-associated antigens like p53 were present, progression-free survival in NSCLC was prolonged. The development of ELI-007 and ELI-008 represents the next level for our current pipeline of lymph node-targeted assets that includes ELI-002, a therapeutic cancer vaccine, which is currently in Cohort 3 of a Phase 1/2 trial in patients with mKRAS tumors. We have prioritized application of our AMP platform to promote immunity against validated cancer targets like BRAF and p53, so the support from GIRF, which is at the forefront of research in the gastrointestinal space including within oncology, is a great opportunity to work together to improve patient outcomes.”
Jackie Casey, J.D., Executive Director, Gastro-Intestinal Research Foundation, added, “Patients have been at the center of our work at GIRF from the very beginning, and this grant is reflective of our mission to transform lives through groundbreaking research. Elicio’s AMP platform has demonstrated the potential to amplify the number of T cells and expand their function with promising data. With directed funds from a generous donor, we are proud to support this innovative biotech company as it pushes boundaries in therapeutic cancer vaccine development.”
About the Amphiphile Platform
Our proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics on to the “brain center” of the immune system – the lymph nodes. We consider this site-specific supply of disease-specific antigens, adjuvants and different immunomodulators might effectively educate, activate and amplify vital immune cells, probably leading to induction and persistence of potent adaptive immunity required to deal with many illnesses. In preclinical fashions, we have now noticed lymph node-specific engagement driving therapeutic immune responses of elevated magnitude, operate and sturdiness. We consider our AMP lymph node-targeted method will produce superior scientific advantages in comparison with immunotherapies that don’t have interaction the lymph nodes.
Our AMP platform, initially developed at the Massachusetts Institute of Technology, or MIT, has broad potential throughout cancers, infectious illnesses and different illness indications to advance plenty of growth initiatives by way of inner actions, in-licensing preparations or growth collaborations and partnerships.
The Amphiphile platform has been proven to ship immunotherapeutics on to the lymph nodes by latching on to the protein albumin, present in the bloodstream, because it travels to lymphatic tissue. In preclinical fashions, we have now noticed lymph node-specific engagement driving therapeutic immune responses of elevated magnitude, operate and sturdiness.
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology firm growing a pipeline of novel immunotherapies for the remedy of most cancers and different illnesses. By combining experience in immunology and immunotherapy, Elicio is engineering investigational Amphiphile immunotherapies which are supposed to exactly goal and absolutely have interaction the lymph nodes, the web site in our our bodies the place the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious illnesses.
Elicio started dosing topics in AMPLIFY-201, its Phase 1/2 scientific trial in stable tumor topics for its lead Amphiphile vaccine, ELI-002, concentrating on KRAS-driven cancers in October 2021. The Amphiphile platform emerged from the laboratories of Darrell Irvine, Howard Hughes Investigator and Professor of Biomedical Engineering in the Koch Institute of Integrative Cancer Research at MIT. For extra data, please go to https://elicio.com/.
Cautionary Note on Forward-Looking Statements
This press launch contains forward-looking statements. Such forward-looking statements contain recognized and unknown dangers, uncertainties, assumptions and different essential components that might trigger our precise outcomes, efficiency or achievements to vary materially from historic outcomes or any future outcomes, efficiency or achievements expressed, steered or implied by such forward-looking statements. Forward-looking statements embody, however aren’t restricted to, statements concerning our expectation to broaden our pipeline by growing ELI-007 and ELI-008 to focus on BRAF V600E mutations and mutations in p53, our perception that the AMP technique is ideally suited to boost tumor-specific immunity with the potential to eradicate tumors and promote sturdy affected person responses, our expectation that the assist from GIRF presents an incredible alternative to work collectively to enhance affected person outcomes, our perception that Elicio’s AMP platform has potential to amplify the variety of T cells and develop their operate and the expectation that we’re pushing boundaries in therapeutic most cancers vaccine growth. Applicable dangers and uncertainties that might trigger our precise outcomes, efficiency or achievements to vary materially from historic outcomes or any future outcomes, efficiency or achievements expressed, steered or implied by our forward-looking statements embody, amongst others: that our analysis doesn’t yield our anticipated outcomes, we establish critical uncomfortable side effects or different issues of safety, we wouldn’t have scientific provide of our product candidate that’s enough in quantity and high quality and provided in a well timed vogue, and the inherent dangers of scientific growth; our restricted working historical past and historic losses; our want to boost capital to fund our analysis and growth packages; the early stage nature of the growth of our product candidates; competitors from numerous opponents in the markets focused by our product candidates, together with from opponents with considerably larger assets than us; our basic dependence on third events in reference to manufacturing, scientific trials and preclinical research; the potential complexity of the manufacturing course of for our product candidates; our means to guard our mental property; our dependence on the patents we license from the Massachusetts Institute of Technology, or MIT; our compliance with healthcare legal guidelines and laws; and dangers regarding the affect on of COVID-19 or different infectious illnesses on our business. The forward-looking statements contained on this press launch replicate our present views with respect to future occasions, and we don’t undertake and particularly disclaim any obligation to replace any forward-looking statements, besides as required by legislation.
Media Contact
Gloria Gasaatura
LifeSci Communications
+1 646-970-4688
[email protected]
